Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
Liver cancer
Molecular genetics
Oncogenes
Oncology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
08 06 2022
08 06 2022
Historique:
received:
03
09
2021
accepted:
26
04
2022
pubmed:
29
4
2022
medline:
10
6
2022
entrez:
28
4
2022
Statut:
epublish
Résumé
Fibrolamellar carcinoma (FLC) is an aggressive liver cancer primarily afflicting adolescents and young adults. Most patients with FLC harbor a heterozygous deletion on chromosome 19 that leads to the oncogenic gene fusion, DNAJB1-PRKACA. There are currently no effective therapeutics for FLC. To address that, it is critical to gain deeper mechanistic insight into FLC pathogenesis. We assembled a large sample set of FLC and nonmalignant liver tissue (n = 52) and performed integrative multiomic analysis. Specifically, we carried out small RNA sequencing to define altered microRNA expression patterns in tumor samples and then coupled this analysis with RNA sequencing and chromatin run-on sequencing data to identify candidate master microRNA regulators of gene expression in FLC. We also evaluated the relationship between DNAJB1-PRKACA and microRNAs of interest in several human and mouse cell models. Finally, we performed loss-of-function experiments for a specific microRNA in cells established from a patient-derived xenograft (PDX) model. We identified miR-10b-5p as the top candidate pro-proliferative microRNA in FLC. In multiple human cell models, overexpression of DNAJB1-PRKACA led to significant upregulation of miR-10b-5p. Inhibition of miR-10b in PDX-derived cells increased the expression of several potentially novel target genes, concomitant with a significant reduction in metabolic activity, proliferation, and anchorage-independent growth. This study highlights a potentially novel proliferative axis in FLC and provides a rich resource for further investigation of FLC etiology.
Identifiants
pubmed: 35482409
pii: 154743
doi: 10.1172/jci.insight.154743
pmc: PMC9220943
doi:
pii:
Substances chimiques
DNAJB1 protein, human
0
HSP40 Heat-Shock Proteins
0
MIRN10 microRNA, human
0
MIRN10 microRNA, mouse
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : P01 DK094779
Pays : United States
Références
Curr Med Chem. 2008;15(25):2641-7
pubmed: 18855684
Am J Cancer Res. 2018 Sep 01;8(9):1674-1688
pubmed: 30323962
PLoS One. 2022 Feb 15;17(2):e0263829
pubmed: 35167623
Semin Diagn Pathol. 2017 Mar;34(2):146-152
pubmed: 28110996
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):E5916-25
pubmed: 26489647
Gastroenterology. 2015 Apr;148(4):806-18.e10
pubmed: 25557953
J Integr Bioinform. 2016 Dec 22;13(5):307
pubmed: 28187421
Science. 2014 Feb 28;343(6174):1010-4
pubmed: 24578576
J Biol Chem. 2012 Apr 13;287(16):13026-39
pubmed: 22318730
Oncotarget. 2017 Dec 15;9(12):10211-10227
pubmed: 29535801
Gastroenterology. 2017 Dec;153(6):1662-1673.e10
pubmed: 28923495
J Biol Chem. 2015 Dec 4;290(49):29250-8
pubmed: 26468277
J Biol Chem. 2010 Nov 19;285(47):36721-35
pubmed: 20843787
Sci Rep. 2017 Mar 17;7:44653
pubmed: 28304380
Oncol Rep. 2017 Apr;37(4):2449-2458
pubmed: 28350134
PLoS One. 2019 Apr 17;14(4):e0204387
pubmed: 30995246
EMBO Rep. 2016 May;17(5):648-58
pubmed: 27113763
Genes Dev. 2006 Aug 15;20(16):2202-7
pubmed: 16882971
Cancer Manag Res. 2020 Feb 27;12:1483-1492
pubmed: 32161500
EMBO J. 2005 Jan 26;24(2):418-27
pubmed: 15616572
Cancer Res. 2005 Nov 1;65(21):9807-16
pubmed: 16267002
Tumour Biol. 2017 Mar;39(3):1010428317695916
pubmed: 28345456
Nat Commun. 2015 Oct 06;6:8070
pubmed: 26437858
Bioinformatics. 2011 Apr 1;27(7):1017-8
pubmed: 21330290
Gastroenterology. 2021 Nov;161(5):1584-1600
pubmed: 34245764
World J Surg Oncol. 2016 May 23;14(1):151
pubmed: 27215576
Cells. 2021 Apr 16;10(4):
pubmed: 33923648
Mod Pathol. 2017 Jun;30(6):892-896
pubmed: 28256571
Tumour Biol. 2012 Oct;33(5):1455-65
pubmed: 22528944
Gut. 2013 Nov;62(11):1667-8
pubmed: 23708586
Gastrointest Cancer Res. 2013 Jan;6(1):3-9
pubmed: 23505572
J Clin Invest. 2007 May;117(5):1440-9
pubmed: 17431503
J Transl Med. 2021 Dec 20;19(1):521
pubmed: 34930316
J Gastrointest Surg. 2016 Oct;20(10):1725-31
pubmed: 27456016
Cancers (Basel). 2021 Aug 03;13(15):
pubmed: 34359820
Oncotarget. 2017 Jul 12;8(52):89620-89630
pubmed: 29163775
Arch Med Res. 2018 Nov;49(8):530-537
pubmed: 30642654
Hum Mol Genet. 2015 Jan 1;24(1):50-63
pubmed: 25122662
Gene. 2016 Nov 5;592(2):308-15
pubmed: 27451075
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
PLoS One. 2013 Sep 09;8(9):e73240
pubmed: 24039891
Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13076-13084
pubmed: 29162699
Mod Pathol. 2020 Apr;33(4):648-656
pubmed: 31676785
Cell Mol Gastroenterol Hepatol. 2019;7(4):803-817
pubmed: 30763770
J Am Coll Surg. 2014 Feb;218(2):196-205
pubmed: 24315886
Neoplasma. 2022 Mar;69(2):370-382
pubmed: 35081724
Cell Rep. 2020 Apr 14;31(2):107509
pubmed: 32294439
Elife. 2019 May 07;8:
pubmed: 31063128
Oncol Lett. 2019 Feb;17(2):1401-1408
pubmed: 30675193
Dig Dis Sci. 2021 Jan;66(1):308-314
pubmed: 32052215
Mol Ther Nucleic Acids. 2018 Mar 2;10:215-226
pubmed: 29499934
Mod Pathol. 2018 Jan;31(1):141-149
pubmed: 28862261
Science. 2016 Mar 4;351(6277):aad3680
pubmed: 26941323
PLoS One. 2017 May 9;12(5):e0176562
pubmed: 28486549
Mol Cancer Res. 2013 Sep;11(9):1017-28
pubmed: 23723077
Nucleic Acids Res. 2022 Jan 7;50(D1):D165-D173
pubmed: 34850907
Am J Transl Res. 2017 May 15;9(5):2207-2218
pubmed: 28559972
Oncogene. 2015 Jul 23;34(30):3946-56
pubmed: 25263439
Sci Rep. 2015 Dec 10;5:17940
pubmed: 26658802